Create an Account
  1. Home
  2. Specialty
  3. General Ophthalmology

Geographic Atrophy: What to Look For and When to Refer

ReachMD Healthcare Image
Program Information
Take Pre-Test

The live program has concluded.


If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.

Scroll back to top
Details

  • Overview

    Prevalence of GA underscores the need for clinicians to reliably detect, characterize, & measure the disease. Burden & demographics associated with GA, options for imaging, classifying disease based on presentation characteristics, & evaluating progression of GA will be reviewed.

    By learning the dynamics of the biologic pathways that mediate GA clinicians may better understand the targets of various investigative therapies. Delve into the particulars of the complement system & learn about pipeline therapies under investigation for the treatment of GA!

    Supported by an unrestricted educational grant from Apellis.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Articulate the burden of illness linked to geographic atrophy (GA)
    • Describe disease detection and factors influencing progression
    • Discuss the prevalence of age-related macular degeneration
    • Understand the pathogenesis of GA
    • Review the therapeutic interventions that have been explored as well as those in the pipeline

    • Accreditation

      This educational activity is provided by Evolve Medical Education LLC (Evolve).

      ​

      Accreditation Statement
      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Sponsored by​​​  

      Evolve Medical Education LLC (Evolve) is a COPE accredited administrator. This activity, COPE Activity Number 123440, is accredited by COPE for continuing education for optometrists for 2 hours.

      Course #: 76934-TD
      Activity #: 123440

       

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

      Course Viewing Requirements

      Supported Browsers:
      Internet Explorer 11 for Windows
      Edge (recent versions; Chromium-based) for Windows
      Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
      Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
      Safari (recent versions) for Mac OSX, or iOS

      Hardware Requirements:
      4GB+ RAM
      Recommended internet speed 5Mbps+

       

    • Faculty and Disclosures

      Roger A. Goldberg, MD, MBA

      Roger A. Goldberg, MD, MBA

      Vitreoretinal Specialist
      Bay Area Retina Associates
      Walnut Creek, CA


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Roger A. Goldberg, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Carl Zeiss Meditec, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Aerie Pharmaceuticals, Allergan, Apellis Pharmaceuticals, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Neurotech, Novartis, Ribomics, and Santen. Speaker’s Bureau: Allergan and Genentech.

      The Evolve staff, planners, and reviewer, have no financial relationships with ineligible companies.
      Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Expiration Date:

    2.00 credits
    Completing the pre-test is required to access this content.
    Completing the pre-survey is required to view this content.

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free